Identification of RNA markers associated with Parkinson's disease using multiplex gene expression analysis
- 作者: Ardashirova N.1, Abramycheva N.1, Fedotova E.1, Sukhorukov V.1, Voronkova A.1, Mudzhiri N.1, Illarioshkin S.1
-
隶属关系:
- Research Center of Neurology
- 期: 卷 16, 编号 4 (2022)
- 页面: 38-43
- 栏目: Original articles
- URL: https://journals.rcsi.science/2075-5473/article/view/124051
- DOI: https://doi.org/10.54101/ACEN.2022.4.5
- ID: 124051
如何引用文章
全文:
详细
Introduction. Parkinson's disease (PD) is a neurodegenerative disorder, and the development of biomarkers is essential due to complicated PD diagnosis and progression assessment.
Objective. To identify PD RNA markers by multiplex expression profiling of 760 genes associated with the main neuropathological processes.
Materials and methods. We studied the expression of 760 genes associated with the main neuropathological processes using Nanostring nCounter® Human Neuropathology Panel in 29 blood samples obtained from PD patients, including 13 samples from those in the early stage and 16 samples from those in the advanced stage, and in 16 control blood samples.
Results. The comparison of gene expression in the patients with early PD and in the controls demonstrated differential expression of genes CDKN1A and CPT1B. The comparison of gene expression in the patients with advanced PD and in the controls showed LRP1 upregulation in the advanced PD group. We also revealed СPT1B upregulation in advanced disease, with a positive correlation between СPT1B expression and PD duration.
Discussion. The variably expressed genes may be relevant as PD biomarkers for diagnosis and progression assessment.
作者简介
Natalia Ardashirova
Research Center of Neurology
Email: ardashirova.n@yandex.ru
ORCID iD: 0000-0002-4813-9912
PhD student, Neurogenetic department
俄罗斯联邦, 125367, Moscow, Volokolamskoye shosse, 80Natalia Abramycheva
Research Center of Neurology
Email: nataabr@rambler.ru
ORCID iD: 0000-0001-9419-1159
Cand. Sci. (Biol.), leading researcher, Head, DNA laboratory, Neurogenetic department
俄罗斯联邦, 125367, Moscow, Volokolamskoye shosse, 80Ekaterina Fedotova
Research Center of Neurology
Email: ekfedotova@gmail.com
ORCID iD: 0000-0001-8070-7644
D. Sci. (Med.), Head, Neurogenetic department
俄罗斯联邦, 125367, Moscow, Volokolamskoye shosse, 80Vladimir Sukhorukov
Research Center of Neurology
Email: vsukhorukov@gmail.com
ORCID iD: 0000-0002-0552-6939
D. Sci. (Med.), Prof., Head, Neuromorphology laboratory
俄罗斯联邦, 125367, Moscow, Volokolamskoye shosse, 80Anastasiya Voronkova
Research Center of Neurology
Email: anast.voronkova@gmail.com
ORCID iD: 0000-0001-5788-5178
Cand. Sci. (Biol.)
俄罗斯联邦, 125367, Moscow, Volokolamskoye shosse, 80Natalia Mudzhiri
Research Center of Neurology
Email: Mudzhirinm@gmail.com
ORCID iD: 0000-0002-3835-6622
junior researcher, Neuromorphology laboratory
俄罗斯联邦, 125367, Moscow, Volokolamskoye shosse, 80Sergey Illarioshkin
Research Center of Neurology
编辑信件的主要联系方式.
Email: ardashirova.n@yandex.ru
ORCID iD: 0000-0002-2704-6282
D. Sci. (Med.), Prof., RAS Full Member, Deputy Director for Science; Director, Brain Institute
俄罗斯联邦, 125367, Moscow, Volokolamskoye shosse, 80参考
- Erkkinen M.G., Kim M.O., Geschwind M.D. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb. Perspect. Biol. 2018; 10(4): a033118. doi: 10.1101/cshperspect.a033118
- Tysnes O.B., Storstein A. Epidemiology of Parkinson’s disease. J. Neural. Transm. 2017; 124(8): 901–905. doi: 10.1007/s00702-017-1686-y
- Kalinderi K., Bostantjopoulou S., Fidani L. The genetic background of Parkinson’s disease: current progress and future prospects. Acta Neurol. Scand. 2016; 134(5): 314–326. doi: 10.1111/ane.12563
- Deng H., Wang P., Jankovic J. The genetics of Parkinson disease. Ageing Res. Rev. 2018; 42: 72–85. doi: 10.1016/j.arr.2017.12.007
- Cheng H.C., Ulane C.M., Burke R.E. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 2010; 67(6): 715–725. doi: 10.1002/ana.21995
- Postuma R.B., Berg D., Stern M. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 2015; 30(12): 1591–1601. doi: 10.1002/mds.26424
- Rizzo G., Copetti M., Arcuti S. et al. Accuracy of clinical diagnosis of Parkinson disease. Neurology. 2016; 86(6): 566–576. doi: 10.1212/WNL.0000000000002350
- Armstrong M.J., Okun M.S. Diagnosis and treatment of Parkinson disease. JAMA. 2020; 323(6): 548. doi: 10.1001/jama.2019.22360
- Vijiaratnam N., Simuni T., Bandmann O. et al. Progress towards therapies for disease modification in Parkinson’s disease. Lancet Neurol. 2021; 20(7): 559–572. doi: 10.1016/S1474-4422(21)00061-2
- Lang A.E., Espay A.J. Disease modification in Parkinson’s disease: current approaches, challenges, and future considerations. Mov. Disord. 2018; 33(5): 660–677. doi: 10.1002/mds.27360
- Parnetti L., Gaetani L., Eusebi P. et al. CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol. 2019; 18(6): 573–586. doi: 10.1016/S1474-4422(19)30024-9
- Goytain A., Ng T. NanoString nCounter technology: high-throughput RNA validation. Methods Mol. Biol. 2020; 2079: 125–139. doi: 10.1007/978-1-4939-9904-0_10
- Santiago J.A., Potashkin J.A. Evaluation of RNA blood biomarkers in individuals at risk of Parkinson’s disease. J. Parkinsons Dis. 2017; 7(4): 653–660. doi: 10.3233/JPD-171155
- Santiago J.A., Bottero V., Potashkin J.A. Evaluation of RNA blood biomarkers in the Parkinson’s disease biomarkers program. Front Aging Neurosci. 2018; 10: 157. doi: 10.3389/fnagi.2018.00157
- Shamir R., Klein C., Amar D. et al. Analysis of blood-based gene expression in idiopathic Parkinson disease. Neurology. 2017; 89(16): 1676–1683. doi: 10.1212/WNL.0000000000004516
- Scherzer C.R., Eklund A.C., Morse L.J. et al. Molecular markers of early Parkinson’s disease based on gene expression in blood. Proc. Nat. Acad. Sci. 2007; 104(3): 955–960. doi: 10.1073/pnas.0610204104
- Liu X., Wang Q., Yang Y. et al. Reduced erythrocytic CHCHD2 mRNA is associated with brain pathology of Parkinson’s disease. Acta Neuropathol. Commun. 2021; 9(1): 37. doi: 10.1186/s40478-021-01133-6
- Lanke V., Moolamalla S.T.R., Roy D., Vinod P.K. Integrative analysis of hippocampus gene expression profiles identifies network alterations in aging and Alzheimer’s disease. Front. Aging Neurosci. 2018; 10: 153. doi: 10.3389/fnagi.2018.00153
- Santos-Lobato B.L., Vidal A.F., Ribeiro-dos-Santos Â. Regulatory miRNA–mRNA networks in Parkinson’s disease. Cells. 2021; 10(6): 1410. doi: 10.3390/cells10061410
- Pattarini R., Rong Y., Shepherd K.R. et al. Long-lasting transcriptional refractoriness triggered by a single exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine. Neuroscience. 2012; 214: 84–105. doi: 10.1016/j.neuroscience.2012.03.047
- Yang L., Liu C.C., Zheng H. et al. LRP1 modulates the microglial immune response via regulation of JNK and NF-κB signaling pathways. J. Neuroinflammation. 2016; 13(1): 304. doi: 10.1186/s12974-016-0772-7
- Wilhelmus M.M.M., Bol J.G.J.M., van Haastert E.S. et al. Apolipoprotein E and LRP1 increase early in Parkinson’s disease pathogenesis. Am. J. Pathol. 2011; 179(5): 2152–2156. doi: 10.1016/j.ajpath.2011.07.021
- Strauss K.M., Martins L.M., Plun-Favreau H. et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum. Mol. Genet. 2005; 14(15): 2099–2111. doi: 10.1093/hmg/ddi215
- Li W., Fu Y., Halliday G.M., Sue C.M. PARK genes link mitochondrial dysfunction and alpha-synuclein pathology in sporadic Parkinson’s disease. Front. Cell Dev. Biol. 2021; 9. doi: 10.3389/fcell.2021.612476
- Сухоруков В.С., Воронкова А.С., Литвинова Н.А. и др. Роль индивидуальных особенностей митохондриальной ДНК в патогенезе болезни Паркинсона. Генетика. 2020; 56(4): 392–400. Sukhorukov V.S., Voronkova A.S., Litvinova N.A. The role of individual features of mitochondrial DNA in the pathogenesis of Parkinson’s disease. Genetics. 2020; 56(4): 392–400. (In Russ.) doi: 10.31857/S0016675820040141
- Devi L., Raghavendran V., Prabhu B.M. et al. Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008; 283(14): 9089–9100. doi: 10.1074/jbc.M710012200
- Malpartida A.B., Williamson M., Narendra D.P. et al. Mitochondrial dysfunction and mitophagy in Parkinson’s disease: from mechanism to therapy. Trends Biochem. Sci. 2021; 46(4): 329–343. doi: 10.1016/j.tibs.2020.11.007
- Park J.S., Davis R.L., Sue C.M. Mitochondrial dysfunction in Parkinson’s disease: new mechanistic insights and therapeutic perspectives. Curr. Neurol. Neurosci. Rep. 2018; 18(5): 21. doi: 10.1007/s11910-018-0829-3
- Balestrino R., Schapira A.H.V. Parkinson disease. Eur. J. Neurol. 2020; 27(1): 27–42. doi: 10.1111/ene.14108
- Sevigny J., Chiao P., Bussière T. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016; 537(7618): 50–56. doi: 10.1038/nature19323